Amolyt Pharma Agrees to Be Acquired by AstraZeneca in up to $1.05 Billion Cross-Border Transaction

New York – March 14, 2024 – Cooley advised Amolyt Pharma, a global clinical-stage biopharmaceutical company based in Lyon, France, that specializes in developing therapeutic peptides for rare endocrine and related diseases, on its definitive agreement to be acquired by AstraZeneca for up to $1.05 billion in cash. Partners Jamie Leigh, Bill Roegge, Laura Berezin and Marc Recht led the Cooley team advising Amolyt.

Under the terms of the agreement, AstraZeneca will acquire all of Amolyt’s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt-free basis, consisting of $800 million upfront at deal closing, plus the right for Amolyt’s shareholders to receive an additional contingent payment of $250 million, payable upon achievement of a specified regulatory milestone. Subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances, the transaction is expected to close by the end of Q3 2024.

A Cooley team led by Laura Berezin and Marc Recht has advised Amolyt, one of the top private biotechnology companies in France, since 2021.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.